icotyde approved. no segmentation guidance. cool.
Company: Johnson & Johnson (Janssen)
Tags: launch, field, strategy
"icotyde for appropriate new patients, tremfya remains excellent" is not a strategy its a dodge going into derm accounts tomorrow and winging it. on a $5B launch. great.
12 upvotes · 5 comments